Abivax S.A.
NASDAQ:ABVX · NASDAQ Global Market
-$0.62 today
Vol 1.68M · Avg 1.59M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:ABVX · Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$427.2M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-5.84, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $0 | $0 | $0 -100.0% | $50.8M +11.5% | $45.5M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $0 | $0 | $0 +100.0% | -$50.8M -11.5% | -$45.5M | $8.9B | $7.6B | $6.2B |
| Gross Margin | — | — | — | — | — | 9.8% | 28.9% | 38.3% |
| Research & Development | $177.8M +21.3% | $146.5M +42.0% | $103.2M +113.6% | $48.3M +1.1% | $47.8M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $72.9M +87.3% | $38.9M +35.0% | $28.8M +284.7% | $7.5M +34.3% | $5.6M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $246.1M +42.2% | $173.0M +35.8% | $127.4M +805.2% | $14.1M +441.8% | -$4.1M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $1.1M -2.5% | $1.1M +55.6% | $707.0K +45.8% | $485.0K +60.6% | $302.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$300.7M -84.8% | -$162.7M -22.1% | -$133.2M -149.8% | -$53.3M -38.2% | -$38.6M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | — | — | — | — | — | 5.6% | 46.3% | 42.0% |
| Operating Income | -$246.1M -42.2% | -$173.0M -35.8% | -$127.4M -96.5% | -$64.8M -56.6% | -$41.4M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | — | — | — | — | — | 16.6% | 24.1% | 22.0% |
| Interest Income | $5.8M -35.8% | $9.0M +223.0% | $2.8M | $0 | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $28.5M +129.1% | $12.4M -10.1% | $13.8M +99.2% | $6.9M +95.1% | $3.6M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$84.2M -2484.3% | -$3.3M +84.0% | -$20.4M -597.2% | $4.1M +489.4% | -$1.1M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$330.3M -87.4% | -$176.2M -19.3% | -$147.7M -143.2% | -$60.7M -43.1% | -$42.5M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | — | — | — | — | — | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $5.8M | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$336.1M -90.7% | -$176.2M -19.3% | -$147.7M -143.2% | -$60.7M -43.1% | -$42.5M | $4.9B | $4.8B | $4.7B |
| Net Margin | — | — | — | — | — | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$5 -66.1% | -$3 +18.4% | -$3 -7.9% | -$3 -15.6% | -$3 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$5 -66.1% | -$3 +18.4% | -$3 -7.9% | -$3 -15.6% | -$3 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $69.5M +10.3% | $63.0M +46.4% | $43.1M +125.6% | $19.1M +23.5% | $15.5M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $69.5M +10.3% | $63.0M +46.4% | $43.1M +125.6% | $19.1M +23.5% | $15.5M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Jazz Pharmaceuticals plc
NASDAQ:JAZZ
$14.17B
Axsome Therapeutics, Inc.
NASDAQ:AXSM
$12.94B
Madrigal Pharmaceuticals, Inc.
NASDAQ:MDGL
$11.67B
Cytokinetics, Incorporated
NASDAQ:CYTK
$9.86B
Nuvalent, Inc.
NASDAQ:NUVL
$9.08B
Corcept Therapeutics Incorporated
NASDAQ:CORT
$8.88B
Halozyme Therapeutics, Inc.
NASDAQ:HALO
$8.08B
Metsera, Inc.
MTSR
$7.43B
Merus N.V.
MRUS
$6.83B
Rhythm Pharmaceuticals, Inc.
NASDAQ:RYTM
$6.81B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does ABVX generate?
Abivax S.A. (ABVX) reported $0.00 of revenue in fiscal 2025.
Is ABVX profitable?
Abivax S.A. (ABVX) reported -$336,102,000.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.